

Next-gen haemostatic technology launches in India

30 March 2022 | News

Acts as a catalyst in the clot formation process



SeraSeal, an innovative primary haemostatic agent designed to stop bleeding on contact and within seconds for arterial haemorrhages, has been launched in India. It consists of agar and bovine factor proteins II a VII a and IX a and X a and acts as a catalyst in the clot formation process. This single-component system can tackle any bleeding situation with the potential to save many lives.

Clinical studies and clinical use have demonstrated SeraSeal's unique formulation to be effective in a wide range of coagulopathies. When SeraSeal is applied to a wound, it does not create inflammation or damage to the tissues allowing the wound healing to occur sooner.

A one-component haemostatic agent SeraSeal requires no mixing or preparation and is available in multiple delivery systems to administer any wound to any part of the body. Controlling bleeding, it reduces the substantial need for blood transfusions, thereby, reducing risk and cost to the patient. In addition, cost savings are realised through SeraSeal by reducing surgical time, wherein in some cases, the savings are as much as 50 per cent and shorter hospital stays.

Ajaypal Singh Randhawa, Founder CEO, Swasth Kare India is hopeful this will bring about a sea-change in the healthcare landscape by reducing blood loss, whole blood units needed, surgical time and tissue conservation, every stage in healthcare will improve.